| zamtocabtagene autoleucel (MB-CART2019.1) / Miltenyi Biotec |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 2 | 110 | US | zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine | Miltenyi Biomedicine GmbH | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma | 12/24 | 12/26 | | |
DALY PED, NCT06508931: Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms |
|
|
| Not yet recruiting | 2 | 31 | NA | zamtocabtagene autoleucel (MB-CART2019.1) | Miltenyi Biomedicine GmbH | B-Cell Neoplasm | 09/29 | 10/29 | | |
NCT03870945: Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) |
|
|
| Completed | 1/2 | 12 | Europe | MB-CART2019.1 Dose level 1, CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells, MB-CART2019.1 Dose level 2 | Miltenyi Biomedicine GmbH, ICON plc | B-cell Non Hodgkin Lymphoma | 12/20 | 05/24 | | |
| Not yet recruiting | 1 | 48 | NA | zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine | Miltenyi Biomedicine GmbH | Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis | 12/26 | 12/26 | | |
| Recruiting | N/A | 40 | Europe | MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells, MB-CART20.1, CD20-targeting CAR T cells, Anti-CD20 CAR T cells, MB-CART2019.1, CD20/CD19-targeting CAR T cells, Anti-CD20/CD19 CAR T cells | Miltenyi Biomedicine GmbH | Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma, Acute Lymphatic Leukemia, Chronic Lymphatic Leukemia, Melanoma Stage IV | 12/40 | 12/40 | | |
NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
|
|
| Not yet recruiting | N/A | 150 | US | Long-term Follow-Up | Miltenyi Biomedicine GmbH | Non Hodgkin Lymphoma | 12/39 | 12/39 | | |
